Search

Your search keyword '"Edelman, Martin J."' showing total 1 results
Start Over Author "Edelman, Martin J." Language undetermined
1 results on '"Edelman, Martin J."'

1. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

Author

Edelman, Martin J., Dvorkin, Mikhail, Laktionov, Konstatin, Navarro, Alejandro, Juan-Vidal, Oscar, Kozlov, Vadim, Golden, Gil, Jordan, Odette, Deng, C. Q., Bentsion, Dmitriy, Chouaid, Christos, Dechev, Hristo, Dowlati, Afshin, Fernández Núñez N, Ivashchuk, Olexandr, Kiladze, Ivane, Kortua, Tsira, Leighl, Natasha, Luft, Aleksandr, Makharadze, Tamta, Min, YoungJoo, Quantin, Xavier, and DISTINCT Study Investigators

Subjects
Dinutuximab, Disialoganglioside, Irinotecan, Second-line treatment, Small cell
Abstract

Topotecan is approved as second-line treatment for small cell lung cancer (SCLC). Irinotecan is also frequently used given its more convenient schedule and superior tolerability. Preclinical studies support disialoganglioside (GD2) as an SCLC target and the combination of dinutuximab, an anti-GD2 antibody, plus irinotecan in this setting. We tested dinutuximab/irinotecan versus irinotecan or topotecan as second-line therapy in relapsed/refractory (RR) SCLC.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results